Ensign Peak Advisors Inc lessened its stake in STAAR Surgical (NASDAQ:STAA - Free Report) by 41.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 310,247 shares of the medical instruments supplier's stock after selling 218,949 shares during the quarter. Ensign Peak Advisors Inc owned about 0.63% of STAAR Surgical worth $7,536,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its holdings in STAAR Surgical by 411.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier's stock worth $7,978,000 after acquiring an additional 172,779 shares during the period. Defender Capital LLC. boosted its holdings in STAAR Surgical by 3.5% in the 4th quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier's stock worth $17,041,000 after acquiring an additional 23,950 shares during the period. KBC Group NV boosted its holdings in STAAR Surgical by 5,700.9% in the 4th quarter. KBC Group NV now owns 96,585 shares of the medical instruments supplier's stock worth $2,346,000 after acquiring an additional 94,920 shares during the period. Raymond James Financial Inc. purchased a new position in STAAR Surgical in the 4th quarter worth approximately $923,000. Finally, Barclays PLC boosted its holdings in STAAR Surgical by 349.4% in the 3rd quarter. Barclays PLC now owns 91,707 shares of the medical instruments supplier's stock worth $3,406,000 after acquiring an additional 71,301 shares during the period. Hedge funds and other institutional investors own 96.70% of the company's stock.
Insider Activity at STAAR Surgical
In related news, major shareholder Broadwood Partners, L.P. bought 259,316 shares of the company's stock in a transaction on Thursday, February 27th. The shares were purchased at an average cost of $17.05 per share, with a total value of $4,421,337.80. Following the completion of the transaction, the insider now directly owns 11,548,753 shares of the company's stock, valued at approximately $196,906,238.65. This represents a 2.30% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have bought 1,482,965 shares of company stock valued at $24,523,688. Corporate insiders own 1.00% of the company's stock.
STAAR Surgical Trading Down 6.3%
STAA stock opened at $19.00 on Wednesday. The firm has a market cap of $940.99 million, a P/E ratio of -46.34 and a beta of 0.65. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $49.86. The stock's 50 day simple moving average is $17.63 and its 200 day simple moving average is $21.77.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on STAA shares. Stephens restated an "equal weight" rating and issued a $17.00 price target on shares of STAAR Surgical in a report on Tuesday, March 18th. Needham & Company LLC reiterated a "hold" rating on shares of STAAR Surgical in a research note on Thursday, February 27th. Mizuho cut STAAR Surgical from an "outperform" rating to a "neutral" rating and reduced their target price for the company from $45.00 to $17.00 in a research note on Wednesday, February 12th. BTIG Research cut STAAR Surgical from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 12th. Finally, William Blair cut STAAR Surgical from an "outperform" rating to a "market perform" rating in a research note on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $24.63.
View Our Latest Report on STAA
STAAR Surgical Profile
(
Free Report)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Featured Articles
Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical (NASDAQ:STAA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider STAAR Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.
While STAAR Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
